RS60122B1 - Kombinovane terapije za lečenje hemorezistentnih kancera - Google Patents
Kombinovane terapije za lečenje hemorezistentnih kanceraInfo
- Publication number
- RS60122B1 RS60122B1 RS20200355A RSP20200355A RS60122B1 RS 60122 B1 RS60122 B1 RS 60122B1 RS 20200355 A RS20200355 A RS 20200355A RS P20200355 A RSP20200355 A RS P20200355A RS 60122 B1 RS60122 B1 RS 60122B1
- Authority
- RS
- Serbia
- Prior art keywords
- compound
- cancer
- hypomethylating agent
- formula
- dna hypomethylating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261720346P | 2012-10-30 | 2012-10-30 | |
| PCT/US2013/067607 WO2014070948A1 (en) | 2012-10-30 | 2013-10-30 | Combination therapies |
| EP13851971.5A EP2914254B1 (en) | 2012-10-30 | 2013-10-30 | Combination therapies to treat chemoresistant cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS60122B1 true RS60122B1 (sr) | 2020-05-29 |
Family
ID=50628036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20200355A RS60122B1 (sr) | 2012-10-30 | 2013-10-30 | Kombinovane terapije za lečenje hemorezistentnih kancera |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20150258068A1 (OSRAM) |
| EP (2) | EP2914254B1 (OSRAM) |
| JP (1) | JP6343285B2 (OSRAM) |
| CA (1) | CA2927565C (OSRAM) |
| CY (1) | CY1123043T1 (OSRAM) |
| DK (1) | DK2914254T3 (OSRAM) |
| ES (1) | ES2774296T3 (OSRAM) |
| HR (1) | HRP20200521T1 (OSRAM) |
| HU (1) | HUE048584T2 (OSRAM) |
| LT (1) | LT2914254T (OSRAM) |
| PL (1) | PL2914254T3 (OSRAM) |
| PT (1) | PT2914254T (OSRAM) |
| RS (1) | RS60122B1 (OSRAM) |
| SI (1) | SI2914254T1 (OSRAM) |
| SM (1) | SMT202000168T1 (OSRAM) |
| WO (1) | WO2014070948A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR046411A1 (es) | 2003-09-22 | 2005-12-07 | S Bio Pte Ltd | Derivados de bencimidazol. aplicaciones farmaceuticas |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| EP2625292B1 (en) | 2010-10-07 | 2018-12-05 | The General Hospital Corporation | Biomarkers of cancer |
| EP3760208B1 (en) | 2014-06-25 | 2024-05-29 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| AR108257A1 (es) * | 2016-05-02 | 2018-08-01 | Mei Pharma Inc | Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| CN112533613A (zh) | 2018-02-06 | 2021-03-19 | 通用医疗公司 | 作为肿瘤免疫应答的生物标志物的重复rna |
| US20220016082A1 (en) * | 2018-11-30 | 2022-01-20 | Mei Pharma, Inc. | Combination therapies for high and very high risk mds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US20100098691A1 (en) * | 2001-01-24 | 2010-04-22 | S'bio Pte Ltd | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
| WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| US20040091951A1 (en) | 2002-02-07 | 2004-05-13 | Axys Pharmaceuticals, Inc. | Assay for measuring acetylation or deacetylation activity of an enzyme |
| US20040038304A1 (en) | 2002-03-28 | 2004-02-26 | Gala Design, Inc. | Antibody libraries |
| PT1937650E (pt) * | 2005-09-08 | 2011-09-21 | S Bio Pte Ltd | Compostos heterocíclicos |
| US7700567B2 (en) * | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| US20110237606A1 (en) * | 2008-09-26 | 2011-09-29 | Agency Of Science, Technology And Research | 3-Deazaneplanocin Derivatives |
-
2013
- 2013-10-30 US US14/440,011 patent/US20150258068A1/en not_active Abandoned
- 2013-10-30 SM SM20200168T patent/SMT202000168T1/it unknown
- 2013-10-30 HR HRP20200521TT patent/HRP20200521T1/hr unknown
- 2013-10-30 EP EP13851971.5A patent/EP2914254B1/en active Active
- 2013-10-30 ES ES13851971T patent/ES2774296T3/es active Active
- 2013-10-30 EP EP19206787.4A patent/EP3662911A1/en not_active Withdrawn
- 2013-10-30 SI SI201331700T patent/SI2914254T1/sl unknown
- 2013-10-30 PT PT138519715T patent/PT2914254T/pt unknown
- 2013-10-30 WO PCT/US2013/067607 patent/WO2014070948A1/en not_active Ceased
- 2013-10-30 HU HUE13851971A patent/HUE048584T2/hu unknown
- 2013-10-30 DK DK13851971.5T patent/DK2914254T3/da active
- 2013-10-30 JP JP2015539952A patent/JP6343285B2/ja not_active Expired - Fee Related
- 2013-10-30 LT LTEP13851971.5T patent/LT2914254T/lt unknown
- 2013-10-30 RS RS20200355A patent/RS60122B1/sr unknown
- 2013-10-30 PL PL13851971T patent/PL2914254T3/pl unknown
- 2013-10-30 CA CA2927565A patent/CA2927565C/en not_active Expired - Fee Related
-
2020
- 2020-04-06 CY CY20201100321T patent/CY1123043T1/el unknown
- 2020-12-15 US US17/122,991 patent/US20210100775A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150258068A1 (en) | 2015-09-17 |
| ES2774296T3 (es) | 2020-07-20 |
| JP2016501838A (ja) | 2016-01-21 |
| CA2927565A1 (en) | 2014-05-08 |
| HRP20200521T1 (hr) | 2020-08-07 |
| EP2914254A4 (en) | 2016-06-29 |
| EP2914254B1 (en) | 2020-01-08 |
| PT2914254T (pt) | 2020-04-02 |
| CY1123043T1 (el) | 2021-10-29 |
| JP6343285B2 (ja) | 2018-06-13 |
| SMT202000168T1 (it) | 2020-05-08 |
| US20210100775A1 (en) | 2021-04-08 |
| HUE048584T2 (hu) | 2020-08-28 |
| EP2914254A1 (en) | 2015-09-09 |
| WO2014070948A1 (en) | 2014-05-08 |
| DK2914254T3 (en) | 2020-03-30 |
| PL2914254T3 (pl) | 2020-09-07 |
| CA2927565C (en) | 2021-05-18 |
| SI2914254T1 (sl) | 2020-07-31 |
| EP3662911A1 (en) | 2020-06-10 |
| LT2914254T (lt) | 2020-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS60122B1 (sr) | Kombinovane terapije za lečenje hemorezistentnih kancera | |
| JP5907396B2 (ja) | 腫瘍融解症候群の治療薬及び予防薬 | |
| CN101910182B (zh) | 抗癌剂 | |
| US20170273952A1 (en) | Methods of treating liver disease | |
| ES2978930T3 (es) | Moduladores de los receptores de arilo y procedimientos de fabricación y utilización de los mismos | |
| TWI620565B (zh) | 治療及預防移植物抗宿主病之方法 | |
| AU2017273771A1 (en) | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases | |
| CN112292128A (zh) | Ep4抑制剂和其用途 | |
| CN107001467A (zh) | C‑c趋化因子受体9型(ccr9)的抑制剂和抗alha4beta7整联蛋白阻断抗体的组合治疗 | |
| WO2018007878A1 (en) | Methods of treating and preventing gout and lead nephropathy | |
| JP2021105005A (ja) | 癌治療 | |
| US20190367503A1 (en) | Compounds and methods of treating or ameliorating an il-1r-mediated disease or disorder using same | |
| WO2022221586A1 (en) | Combination therapy comprising a pkc inhibitor and a mek inhibitor | |
| CA2914742A1 (en) | Handovers with co-operating cells configured to provide coordinated multi-point transmission/reception | |
| JP2022552975A (ja) | 関節リウマチを予防及び／又は治療するためのニコチンアミドモノヌクレオチド（ｎｍｎ）の使用、並びに対応する組成物 | |
| TW201343169A (zh) | 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法 | |
| KR20240158958A (ko) | 암의 치료 및/또는 관리를 위한 stat 억제제와 면역 체크포인트 억제제의 조합 | |
| WO2004009119A1 (ja) | 動脈硬化症治療のための医薬組成物 | |
| TW201924721A (zh) | 包含pi3激酶抑制劑與bcl-2抑制劑的組成物 | |
| CN104606189B (zh) | 一种化合物在制备mTOR抑制剂中的应用 | |
| US20240398846A1 (en) | Treatments for cachexia | |
| CN119454969A (zh) | 含pd-l1小分子抑制剂的药物组合及其应用 | |
| HK40029983A (en) | Combination of azacitidine and pracinostat to treat myelodysplastic syndrome (mds) | |
| WO1993023066A1 (fr) | Promoteur de croissance de plaquettes |